NCT03049540View on ClinicalTrials.gov

Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 25, 2017

Primary Completion Date

October 28, 2021

Study Completion Date

October 28, 2021

Conditions
Heart Defects, CongenitalTransposition of Great Vessels With Ventricular Inversion
Interventions
DRUG

Tadalafil 20 MG

Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil

DRUG

Placebo 20 MG

Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil

Trial Locations (7)

1011

Centre Hospitalier Universitaire Vaudois, Lausanne

1090

Universitätsklinik für Innere Medizin II, Medizinische Universität Wien, Vienna

1205

Hopitaux Universitaires de Geneve, Geneva

3010

Bern University Hospital, Bern

4031

Kardiologie Universitätsspital Basel, Basel

8091

UniversitätsSpital Zürich, Universitäres Herzzentrum, Zurich

9007

Kantonsspital St. Gallen, Sankt Gallen

All Listed Sponsors
collaborator

Swiss National Science Foundation

OTHER

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT03049540 - Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function | Biotech Hunter | Biotech Hunter